Sanofi (SNY) Shares Sold by Dodge & Cox
Dodge & Cox reduced its holdings in Sanofi (NYSE:SNY) by 7.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 62,683,955 shares of the company’s stock after selling 5,293,458 shares during the quarter. Sanofi comprises 2.5% of Dodge & Cox’s portfolio, making the stock its 11th biggest holding. Dodge & Cox owned approximately 2.50% of Sanofi worth $3,003,188,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Pennsylvania Trust Co grew its position in shares of Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock valued at $402,000 after purchasing an additional 37 shares during the last quarter. Rehmann Capital Advisory Group grew its position in shares of Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after purchasing an additional 47 shares during the last quarter. Weik Investment Services Inc. grew its position in Sanofi by 0.9% during the first quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock worth $267,000 after buying an additional 50 shares in the last quarter. Strategic Global Advisors LLC grew its position in Sanofi by 0.6% during the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after buying an additional 54 shares in the last quarter. Finally, Financial Advisors Network Inc. grew its position in Sanofi by 1.0% during the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock worth $409,000 after buying an additional 84 shares in the last quarter. 9.33% of the stock is currently owned by institutional investors.
Sanofi (NYSE SNY) traded up 0.94% during midday trading on Friday, reaching $50.42. The company’s stock had a trading volume of 428,350 shares. The firm has a market cap of $126.63 billion, a P/E ratio of 11.76 and a beta of 0.88. The firm has a 50 day moving average price of $48.38 and a 200-day moving average price of $47.45. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.65.
Sanofi (NYSE:SNY) last released its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. Sanofi’s quarterly revenue was down 2.3% on a year-over-year basis. On average, analysts forecast that Sanofi will post $3.33 earnings per share for the current fiscal year.
A number of equities research analysts recently weighed in on the company. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Friday, June 2nd. HSBC Holdings plc raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus reissued a “buy” rating and set a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. Sanofi has a consensus rating of “Hold” and an average target price of $54.00.
In related news, major shareholder Sanofi purchased 105,820 shares of the stock in a transaction on Thursday, August 24th. The shares were purchased at an average cost of $482.04 per share, with a total value of $51,009,472.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.00% of the stock is owned by corporate insiders.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.